S2Medical AB (OSTO:S2M) WACC %:19.7% (As of Jul. 03, 2026) — 154% Above Median


What is S2Medical AB WACC %?

S2Medical AB OSTO:S2M WACC % is 19.7% as of Jul. 03, 2026, which is 154% above its 10-year median of 7.77. The stock has 3 warning signs investors should review. Among 866 Medical Devices & Instruments companies, S2Medical AB ranks worse than 98.38% on this metric.

As of today (2026-07-03), S2Medical AB's weighted average cost of capital is 19.7%%. S2Medical AB's ROIC % is 0.00% (calculated using TTM income statement data). S2Medical AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


S2Medical AB  (OSTO:S2M) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, S2Medical AB's weighted average cost of capital is 19.7%%. S2Medical AB's ROIC % is 0.00% (calculated using TTM income statement data). S2Medical AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

S2Medical AB WACC % Historical Data

* Premium members only.

The historical data trend for S2Medical AB's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

S2Medical AB WACC % Chart

S2Medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
WACC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.33 9.05 29.27 30.18 38.04

S2Medical AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Jun25 Dec25
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.90 30.46 30.18 27.87 38.04

OSTO:S2M vs ISRG, BDX, MDLN: WACC % Comparison

For the Medical Instruments & Supplies subindustry, S2Medical AB's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


S2Medical AB WACC % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, S2Medical AB's WACC % distribution charts can be found below:

* The bar in red indicates where S2Medical AB's WACC % falls into.



S2Medical AB WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, S2Medical AB's market capitalization (E) is kr4.871 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2025, S2Medical AB's latest one-year quarterly average Book Value of Debt (D) is kr0 Mil.
a) weight of equity = E / (E + D) = 4.871 / (4.871 + 0) = 1
b) weight of debt = D / (E + D) = 0 / (4.871 + 0) = 0

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 2.7446%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. S2Medical AB's beta is 2.8259.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 2.7446% + 2.8259 * 6% = 19.7%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Dec. 2025, S2Medical AB's interest expense (positive number) was kr0.086 Mil. Its total Book Value of Debt (D) is kr0 Mil.
Cost of Debt = 0.086 / 0 = %.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = -1.496 / -1.17 = 127.86%, which is higher than 100%. Therefore it's set to 100%.

S2Medical AB's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=1*19.7%+0*%*(1 - 100%)
=19.7%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 19.7% mean?
S2Medical AB (OSTO:S2M) has a WACC % of 19.7% as of Jul. 03, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on S2Medical AB and its competitors. This is 154% above median its historical median of 7.77. According to the industry distribution chart, S2Medical AB ranks #852 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 98.4%.
Is S2Medical AB's WACC % too high?
S2Medical AB's current WACC % of 19.7% is 154% above median its 10-year median of 7.77. The Medical Devices & Instruments industry median WACC % is 9.22. S2Medical AB's value of 19.7% is 113.8% above this industry median. Based on the distribution chart, S2Medical AB ranks #852 out of 866 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does S2Medical AB's WACC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, S2Medical AB ranks #852 out of 866 companies for WACC %. This places S2Medical AB in the lower half of its industry. The industry median WACC % is 9.22. S2Medical AB's value of 19.7% is 113.8% above this benchmark. While the company's 10-year median is 7.77 vs. the industry median of 9.22, S2Medical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Medical Devices & Instruments company?
The median WACC % among Medical Devices & Instruments companies is 9.22, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. S2Medical AB's current WACC % of 19.7% is 113.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on S2Medical AB and its competitors. For the Medical Devices & Instruments industry, the median WACC % is 9.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. S2Medical AB's current WACC % is 19.7%, which is 154% above median its own 10-year median of 7.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is S2Medical AB stock overvalued right now?
Based on GuruFocus' analysis, S2Medical AB (OSTO:S2M) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.01, compared to a current price of kr0.01 — trading 48% below its estimated fair value. The current WACC % is 19.7%, which is 154% above median its 10-year median of 7.77 and 113.8% above the Medical Devices & Instruments industry median of 9.22. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For S2Medical AB (OSTO:S2M), the current WACC % is 19.7% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

S2Medical AB Business Description

Other Exchanges S21:Germany
Address Sunnorpsgatan 5, Linkoping, SWE, 582 73
S2Medical AB is a research-intensive MedTech company from Sweden. The company develops products within the entire wound healing process from debridement and granulation to re-epithelialization. products for the initial phase of a wound's healing process until the end, when the wound is completely healed. S2Medical also has in its portfolio the product NoSmell for odor removal which is procured in several different Swedish healthcare regions.